Zynerba Pharmaceuticals Inc said on Thursday its cannabis-based gel met the main goal in a mid-stage study of patients with Fragile X syndrome, a genetic disorder that causes learning disabilities in adolescents and children.
Tag Archives: Zynerba Pharmaceuticals
Clinical-stage cannabinoid-based drug developer Zynerba Pharmaceuticals (NASDAQ:ZYNE) had been one of the strongest-performing pot stocks over the trailing year prior to the start of this past week.
Zynerba Pharmaceuticals Inc said on Monday its synthetic cannabis-based gel to treat epilepsy failed a mid-stage study, sending the U.S. drug developer’s shares plunging 50 percent.
In total, four marijuana stocks jumped higher by at least 10% last week. Let’s take a brief look at some of these moves.
There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there’s the third type: the biotechs. Zynerba Pharmaceuticals belongs to the last kind of marijuana stock.
The marijuana industry is the hottest thing since sliced bread, and marijuana stocks are thriving. Here’s a quick rundown of the largest players.
Here are 4 top stocks in the growing medical marijuana industry that have a tremendous amount of potential for investors.
These 5 marijuana stocks lost a combined $193 Million in 2016. Though they’re some of the top performers, they’re also among the companies losing the most money on an annual basis.
Medical marijuana remains the safest investment route — if you’re forced to choose one — so here’s a brief rundown of the cannabinoid-based drugs working their way through clinical and preclinical trials.
A federal crackdown on marijuana isn’t bad news for all marijuana stocks.
DEVON, Pa., Jan. 19, 2017 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the pricing of an underwritten public offering of 2.8 million shares of its common stock at a price of $18.00 per share, with expected gross proceeds to Zynerba of $50.4 million.
While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.
Scientists, regulators and millions suffering from pain are trying to get their hands on cannabis — but not the kind you smoke, eat or grow in an alley.
DEVON, Pa., June 1, 2016 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will participate in various upcoming investor meetings and conferences.